Kazunori Murai

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 297 citations

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +11

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 116 citations · Full text

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai et al. · The Lancet Haematology · 2020 · 100 citations

Hematological Malignancy, Medicine, First-line Dadi Trial +9

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai et al. · The Lancet Haematology · 2021 · 60 citations

Chronic Phase, Low-dose Dasatinib, Hematological Malignancy +8

Platelet demand modulates the type of intravascular protrusion of megakaryocytes in bone marrow

Shugo Kowata, Sumio Isogai, Kazunori Murai et al. · Thrombosis and Haemostasis · 2014 · 45 citations

Biomedical Engineering, Cellular Physiology, Thrombosis +19